PRN: Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report 2017 - Growing Interest in the Genetics of AML - Research and Markets

26/apr/2017 18:45:16 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report 2017 - Growing Interest in the Genetics of AML - Research and Markets


DUBLIN, April 26, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report" report to their offering.

Research and Markets Logo

This report analyzes the worldwide markets for Acute Myeloid Leukemia (AML) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 69 companies including many key and niche players such as -

  • AbbVie Inc. (USA)
  • Actinium Pharmaceuticals, Inc. (USA)
  • Agios Pharmaceuticals, Inc. (USA)
  • Amgen Inc. (USA)
  • Astellas Pharma Inc. (Japan)
  • Astex Pharmaceuticals, Inc. (USA)
  • Celgene Corporation (USA)
  • CTI BioPharma Corp. (USA)
  • Cyclacel Pharmaceuticals, Inc. (USA)
  • Daiichi Sankyo Company Limited (Japan)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Immune Pharmaceuticals Inc. (USA)
  • Janssen-Cilag Limited (UK)
  • Jazz Pharmaceuticals plc (Ireland)
  • MEI Pharma, Inc. (USA)
  • Merus N.V. (The Netherlands)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (USA)
  • Seattle Genetics, Inc. (USA)
  • Stemline Therapeutics, Inc. (USA)
  • Sunesis Pharmaceuticals, Inc. (USA)
  • Tolero Pharmaceuticals, Inc. (USA)

Key Topics Covered:


  • Growing Incidence and Poor Prognosis
  • A Fatal Concoction Creating Significant Unmet Needs
  • Inadequacies Marr Existing Therapeutics; Pipeline Therapies Offer Hope
  • Current and Future Analysis
  • Standard Mode of Treatment for AML
  • An Overview
  • Standard Approved Mode of Therapy for AML by Age Group
  • List of FDA-Approved Chemotherapy Drugs for Treatment of AML
  • Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics


  • Growing Interest in the Genetics of AML
  • Targeted Therapies Hog Limelight in AML Therapeutic Pipeline
  • Select Major AML Therapeutics in Late-Stage Clinical Development
  • Select AML Therapeutics in Phase I and II Clinical Development
  • Future of Vosaroxin Shrouded in Uncertainty
  • Tough Battle Lies Ahead for Guadecitabine
  • CC-486 Eyes Maintenance Therapy Market
  • Drug Targeting Mutant IDH2 Enzyme Enters Pivotal Trials
  • Immunotherapies in Development too Show Promise
  • Annamycin Shows Promise as a Second Line Therapy for AML
  • ADCs' Clinical Trials Depict Mixed Results
  • Research Innovations/Findings in AML Therapeutics
  • Anti-CD98 Antibodies Offer Novel Approach
  • Inhibition of Metabolic Enzyme in AML Pathway Identified as an Promising Option
  • Personalized Vaccine Approach Invades AML Therapeutic R&D
  • Ceramide-based Therapeutic Targets Drug Resistance of AML
  • Fructose
  • Potential Target for AML Therapeutics



  • Chemotherapy
  • The First-Line Treatment for AML
  • Induction Therapy
  • Post Remission or Consolidation Therapy
  • Hematopoietic Stem Cell Transplantation
  • Treatment for Relapsed AML
  • Maintenance
  • Side-Effects of AML Treatment
  • Effects on Bone Marrow, Platelets, Red Cells, and White Cells
  • Other Common Side-Effects
  • Changes in Smell and Taste
  • Vomiting and Nausea
  • Changes in Bowel
  • Mucositis
  • Loss of Hair
  • Loss in Fertility
  • Early Menopause
  • Fatigue
  • Body Image
  • Therapies to Complement AML Medical Treatment


  • Immune Pharmaceuticals to Commence REMAIN Study
  • Precient Doses First Patient in Phase 1b/2 Clinical Trial of PTX-200
  • Stemline Therapeutics Presents Phase 2 Trial Data of SL-401
  • Helsinn and MEI Pharma Announce Phase 2 Trial results of Pracinostat and azacitidine
  • Daiichi Sankyo Announces Safety and Efficacy Data from Phase 1 Study of DS-3032
  • Pfizer Reveals Positive Phase 2 Study Results of glasdegib/PF
  • Teva's Trisenox Gains EU Approval for APL
  • Daiichi Sankyo Begins Patient Enrollment for Phase 3 QuANTUM Trial on Quizartinib
  • GlycoMimetics Doses First Patient in Phase 2 of GMI-1271
  • Seattle Genetics Initiates Phase 3 Clinical Trial for Vadastuximab Talirine
  • ImmunoGen Begins Clinical Study of IMGN779 for Treatment of AML
  • Agios Pharmaceuticals Initiates Phase 1/2 Study of AG-221 in Combination with VIDAZA®
  • Bio-Path Announces Positive Phase II Results of BP1001
  • Sunesis Secures MAA Validation from EMA for Vosaroxin in AML
  • Agios Pharmaceuticals Initiates Phase 1b Study of AG-221
  • EMA Expands Indications of Celgene's VIDAZA®
  • Astellas Pharma Doses First Patient in Phase 3 Registration Trial of ASP2215
  • OXiGENE Initiates Phase 1b/2 Trial of OXi4503
  • Seattle Genetics Initiates Phase 1b Clinical Trial of SGN-CD33A
  • Agios Pharmaceuticals Announces Safety and Efficacy Data from Phase 1 Trial of AG-120
  • MacroGenics Doses First Patient in Phase 1 Study of MGD006


  • MacroGenics Received Orphan Drug Designation for AML Drug Candidate MGD006
  • FDA Puts Hold on Various Phase I Vadastuximab Trials
  • Arog Receives Orphan Drug Designation for Crenolanib in EU
  • FDA Grants Priority Review to Novartis' NDA for PKC412
  • Immune Pharmaceuticals Obtains FDA Assistance in Ceplene® Pivotal Trial
  • Jazz Pharmaceuticals Begins NDA Submission for Vyxeos
  • Celgene to File NDA for AG-221
  • Jazz Pharmaceuticals to Acquire Celator Pharmaceuticals
  • Celgene and Agios Enter into Collaboration with Abbott
  • Celyad Enters into Exclusive Licensing Agreement with Ono
  • Astex Enters into Clinical Trial Collaboration with Genentech
  • AbbVie's venetoclax Receives Orphan Drug Designation from EMA
  • Novartis Bags Breakthrough Status for Midostaurin Therapy in AML
  • AbbVie Obtains Breakthrough Therapy Designation for Venetoclax with HMAs in AML Treatment
  • FDA Clears Hybrigenics to Carry Out Phase II Trials on inecalcitol in AML Patients
  • Hybrigenics Gets Approval to Carry Out Phase II Trials on inecalcitol in AML Patients in France
  • Boehringer and Philogen Team Up to Develop AML Therapeutics
  • Astex Pharmaceuticals' SGI-110/guadecitabine Receives Orphan Drug Designation from FDA
  • Hybrigenics Obtains Orphan Drug Designation from FDA for Inecalcitol in AML Treatment
  • Daiichi Sankyo to Acquire Ambit Biosciences
  • Celgene Takes Over Rights to Blood Cancer Drugs of Agios
  • Karyopharm Therapeutics' Selinexor (KPT-330) Receives Orphan Drug Designation from FDA
  • Otsuka Buys Rights to Dacogen® from Eisai



For more information about this report visit

Media Contact:

Laura Wood, Senior Manager 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl